01

Aclaris’ $50 Million Offering Meets Positive Allergy Trial Data

Aclaris shares fell 7.7% as a discounted $50 million offering outweighed positive Phase 1b data: 58% improvement in 14-patient atopic dermatitis and 59% marker reduction in asthma.